Feeds:
Posts
Comments

Posts Tagged ‘Cyclooxygenase-2’

URO TODAY: Cox-2 cancer inhibitor celecoxib made no difference to 137 prostate cancer patients in a trial at the Johns Hopkins Cancer Centre in Baltimore. READ MORE>

Cyclooxygenase-2 (COX-2) is a potential pharmacologic target for the prevention of various malignancies, including prostate cancer.

We conducted a randomised, double-blind trial to examine the effect of on drug-specific biomarkers from prostate tissue obtained at prostatectomy.

Treatment with four to six weeks of celecoxib had no effect on intermediate biomarkers of prostate carcinogenesis…

We caution against using celecoxib 400 mg twice daily as a preventive agent for prostate cancer in additional studies.

Read Full Post »